$12.85
-1.24 (-8.80%)
Open$13.98
Previous Close$14.09
Day High$13.98
Day Low$12.65
52W High$14.76
52W Low$3.01
Volume—
Avg Volume26.26M
Market Cap3.35B
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+31.9% upside
Current
$12.85
$12.85
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.91M | 243.91M | 233.99M |
| Net Income | — | 21.63M | 22.04M |
| Profit Margin | — | 8.9% | 9.4% |
| EBITDA | — | 48.94M | 46.22M |
| Free Cash Flow | — | 24.46M | 20.15M |
| Rev Growth | — | -3.3% | +11.1% |
| Debt/Equity | — | 0.58 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |